Association Between Circulating Lipids and Future Weight Gain in Individuals With an At-Risk Mental State and in First-Episode Psychosis. (1st July 2020)

• Record Type: Journal Article
• Authors: Lamichhane, Santosh; Dickens, Alex M; Sen, Partho; Laurikainen, Heikki; Borgan, Faith; Suvisaari, Jaana; Hyötyläinen, Tuulia; Howes, Oliver; Hietala, Jarmo; Orešič, Matej
• Is Part Of: Schizophrenia bulletin. Volume 47:Number 1(2021)
• Page Start: 160
• Page End: 169
• Publication Date: 2020-07-01
• Subjects: lipidomics -- metabolomics -- first-episode psychosis -- metabolic co-morbidities -- weight gain; Schizophrenia -- Periodicals; Schizophrenia -- Research -- Periodicals; 616.898005
• DOI: 10.1093/schbul/sbaa087
• Languages: English
• ISSNs: 0586-7614

Abstract

Abstract: Patients with schizophrenia have a lower than average life span, largely due to the increased prevalence of cardiometabolic comorbidities. There is an unmet public health need to identify individuals with psychotic disorders who have a high risk of rapid weight gain and who are at risk of developing metabolic complications. Here, we applied mass spectrometry-based lipidomics in a prospective study comprising 48 healthy controls (CTR), 44 first-episode psychosis (FEP) patients, and 22 individuals at clinical high risk (CHR) for psychosis, from 2 study centers (Turku, Finland and London, UK). Baseline serum samples were analyzed using lipidomics, and body mass index (BMI) was assessed at baseline and after 12 months. We found that baseline triacylglycerols (TGs) with low double-bond counts and carbon numbers were positively associated with the change in BMI at follow-up. In addition, a molecular signature comprised of 2 TGs (TG[48:0] and TG[45:0]) was predictive of weight gain in individuals with a psychotic disorder, with an area under the receiver operating characteristic curve (AUROC) of 0.74 (95% CI: 0.60–0.85). When independently tested in the CHR group, this molecular signature predicted said weight change with AUROC = 0.73 (95% CI: 0.61–0.83). We conclude that molecular lipids may serve as a predictor of weight gain in psychotic disorders in at-risk individuals and may thus provide a useful marker for identifying individuals who are most prone to developing cardiometabolic comorbidities.